Table 2.
Recent clinical trials on COVID-19 and convalescent plasma therapy
| ClinicalTrials.gov Identifier | Status | Title | Study Design | Country |
| Study Type: Interventional (Clinical Trial) | ||||
| NCT04345679 | Not yet recruiting | Anti-COVID-19 Convalescent Plasma Therapy | Study Type: Iterventional (Clinical Trial) Estimated Enrollment: 20 participants Allocation: N/A Intervention Model: Single Group Assignment |
Hungary |
| NCT04345523 | Recruiting | Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 278 participants Allocation: Randomized Intervention Model: Parallel Assignment |
India |
| NCT04345523 | Recruiting | Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 278 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Spain |
| NCT04380935 | Not yet recruiting | Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 60 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Indonesia |
| NCT04356534 | Recruiting | Convalescent Plasma Trial in COVID -19 Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 40 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Bahrain |
| NCT04359810 | Recruiting | Plasma Therapy of COVID-19 in Critically Ill Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 105 participants Allocation: Randomized Intervention Model: Parallel Assignment |
United States |
| NCT04372979 | Not yet recruiting | Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 80 participants Allocation: Randomized Intervention Model: Parallel Assignment |
France |
| NCT04361253 | Recruiting | Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 220 participants Allocation: Randomized Intervention Model: Parallel Assignment |
United States |
| NCT04403477 | Recruiting | Convalescent Plasma Therapy in Severe COVID-19 Infection | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 20 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Bangladesh |
| NCT04342182 | Recruiting | Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 426 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Netherlands |
| NCT04377568 | Not yet recruiting | Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 100 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Canada |
| NCT04389944 | Recruiting | Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 15 participants Allocation: N/A Intervention Model: Single Group Assignment |
Switzerland |
| NCT04358783 | Recruiting | Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 30 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Mexico |
| NCT04390178 | Active, not recruiting | Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) | Study Type: Interventional (Clinical Trial) Actual Enrollment: 10 participants Allocation: N/A Intervention Model: Single Group Assignment |
Sweden |
| NCT04377568 | Enrolling by invitation | Convalescent Plasma in the Treatment of COVID 19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 100 participants Allocation: Randomized Intervention Model: Parallel Assignment |
United States |
| NCT04384497 | Recruiting | Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 15 participants Allocation: N/A Intervention Model: Single Group Assignment |
Sweden |
| NCT04383535 | Not yet recruiting | Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 333 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Argentina |
| NCT04355897 | Recruiting | CoVID-19 Plasma in Treatment of COVID-19 Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 100 participants Allocation: N/A Intervention Model: Single Group Assignment |
United States |
| NCT04385186 | Not yet recruiting | Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 60 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Colombia |
| NCT04389710 | Recruiting | Convalescent Plasma for the Treatment of COVID-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 100 participants Allocation: N/A Intervention Model: Single Group Assignment |
United States |
| NCT04391101 | Not yet recruiting | Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 231 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Colombia |
| NCT04343755 | Recruiting | Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 55 participants Allocation: N/A Intervention Model: Single Group Assignment |
United States |
| NCT04393727 | Recruiting | Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 126 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Italy |
| NCT04395170 | Not yet recruiting | Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 75 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Colombia |
| NCT04383548 | Not yet recruiting | Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 100 participants Allocation: N/A Intervention Model: Single Group Assignment |
Egypt |
| NCT04374149 | Not yet recruiting | Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 20 participants Allocation: Non-Randomized Intervention Model: Sequential Assignment |
United States |
| NCT04321421 | Recruiting | Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 72 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Spain |
| NCT04376034 | Recruiting | Convalescent Plasma Collection and Treatment in Pediatrics and Adults | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 240 participants Allocation: Non-Randomized Intervention Model: Sequential Assignment |
United States |
| NCT04321421 | Completed | Hyperimmune Plasma for Critical Patients With COVID-19 | Study Type: Interventional (Clinical Trial) Actual Enrollment: 49 participants Allocation: N/A Intervention Model: Single Group Assignment |
Italy |
| NCT04397757 | Recruiting | COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 80 participants Allocation: Randomized Intervention Model: Parallel Assignment |
United State |
| NCT04333355 | Recruiting | Safety in Convalescent Plasma Transfusion to COVID-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 20 participants Allocation: N/A Intervention Model: Single Group Assignment |
Mexico |
| NCT04357106 | Recruiting | COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 10 participants Allocation: N/A Intervention Model: Single Group Assignment |
Mexico |
| NCT04374565 | Recruiting | Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 29 participants Allocation: N/A Intervention Model: Single Group Assignment |
United States |
| NCT04345991 | Recruiting | Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 120 participants Allocation: Randomized Intervention Model: Parallel Assignment |
France |
| NCT04385043 | Recruiting | Hyperimmune Plasma in Patients With COVID-19 Severe Infection | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 400 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Italy |
| NCT04381858 | Recruiting | Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 500 participants Allocation: Randomized Intervention Model: Parallel Assignment |
Mexico |
| NCT04340050 | Active, not recruiting | COVID-19 Convalescent Plasma | Study Type: Interventional (Clinical Trial) Actual Enrollment: 10 participants Allocation: N/A Intervention Model: Single Group Assignment |
United States |
| NCT04362176 | Recruiting | Passive Immunity Trial of Nashville II for COVID-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 500 participants Allocation: Randomized Intervention Model: Parallel Assignment |
United States |
| NCT04356482 | Not yet recruiting | Convalescent Plasma For Ill Patients By Covid-19 | Study Type: Interventional (Clinical Trial) Estimated Enrollment: 90 participants Allocation: N/A Intervention Model: Single Group Assignment |
Mexico |
| Study Type: Observational | ||||
| NCT04292340 | Recruiting | Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 | Study Type: Observational Estimated Enrollment: 15 participants Observational Model: Case-Only Time Perspective: Prospective |
China |
| NCT04334876 | Not yet recruiting | Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers | Study Type: Observational Estimated Enrollment: 340 participants Observational Model: Ecologic or Community Time Perspective: Prospective |
Indiana |
| NCT04360278 | Recruiting | Plasma Collection from Convalescent and/or Immunized Donors for the Treatment of COVID-19 | Study Type: Observational Estimated Enrollment: 1500 participants Observational Model: Cohort Time Perspective: Prospective |
United States |
| Study Type: Expanded Access (Compassionate Use) | ||||
| NCT04360486 | Available | Treatment of coronavirus disease 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | Study Type: Expanded Access Expanded Access Type: Treatment IND/Protocol |
U.S. Army Medical Research and Development Command |
| NCT04363034 | Available | Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program | Study Type: Expanded Access Expanded Access Type: Intermediate-size Population |
United States |
| NCT04338360 | Available | Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | Study Type: Expanded Access Expanded Access Type: Intermediate-size Population |
United States |
| NCT04372368 | Available | Convalescent Plasma for the Treatment of Patients With COVID-19 | Study Type: Expanded Access Expanded Access Type: Treatment IND/Protocol |
United States |
COVID -19: Corona virus disease 2019, SARS – COV -2: Severe Acute Respiratory Syndrome Corona virus 2, ELISA: Enzyme linked immunosorbent assay, ARDS: Acute respiratory distress syndrome, SOFA: Sequential organ function assessment, RT PCR: Reverse Transcriptase Polymerase chain reaction, IgG: Immunoglobulin G, CRP: C Reactive protein, IL 6: Interleukin 6.